Research agreement to expand personalized medicine to prostate cancer
The agreement will establish the feasibility of coupling genomics to Raman spectroscopy to better determine disease progression in prostate cancer.
Predictive Oncology (Minneapolis, MN), which focuses on applying artificial intelligence (AI) to personalized medicine and drug discovery, has signed a collaborative research agreement with molecular imaging company ChemImage (Pittsburgh, PA) to establish the feasibility of coupling genomics to Raman spectroscopy to better determine disease progression in prostate cancer.
Under the agreement, ChemImage will share a set of human prostate tissue (biopsy and prostatectomy) samples with Predictive Oncology subsidiary Helomics, which Helomics will sequence to better understand whether the combination of genomics (mutations and gene expression) and Raman imaging will provide insights to prostate cancer progression. Helomics also plans to integrate the data from these prostate cancer samples, together with its internal database of over 150,000 tumor cases into its D-CHIP AI-powered bioinformatics platform to build a predictive model of prostate cancer drug response.